The present invention relates to heart valve replacement and, in particular, to collapsible prosthetic heart valves. More particularly, the present invention relates to collapsible prosthetic heart valves.
Prosthetic heart valves that are collapsible to a relatively small circumferential size can be delivered into a patient less invasively than valves that are not collapsible. For example, a collapsible valve may be delivered into a patient via a tube-like delivery apparatus such as a catheter, a trocar, a laparoscopic instrument, or the like. This collapsibility can avoid the need for a more invasive procedure such as full open-chest, open-heart surgery.
Collapsible prosthetic heart valves typically take the form of a valve assembly or structure mounted on a stent. There are many types of stents that may be used. However, two types of stents on which the valve structures are ordinarily mounted include: a self-expanding stent and a balloon-expandable stent. To place such valves into a delivery apparatus and ultimately into a patient, the valve must first be collapsed or crimped to reduce its circumferential size.
When a collapsed prosthetic valve has reached the desired implantation site in the patient (e.g., at or near the annulus of the patient's heart valve that is to be replaced by the prosthetic valve), the prosthetic valve can be deployed or released from the delivery apparatus and expanded to the full operating size. For balloon-expandable stents, this generally involves releasing the entire valve, assuring its proper location, and then expanding a balloon positioned within the stent. For self-expanding stents, on the other hand, the stent automatically expands as the sheath covering the valve is withdrawn.
The leaflets in a collapsible prosthetic heart valve, over their useful life, must open and close millions of times. This repeated movement can cause various stresses on the leaflets and, in particular, where they are secured to the rest of the valve. Improper or inadequate attachment can lead to tearing of pulling away from the stent and failure of the valve. And valve failure, in the circulatory system, can have significant consequences for the patient. Accordingly, there remains a need for improved methods of producing heart valves and securing valve leaflets in collapsible prosthetic heart valves.
The present disclosure relates to prosthetic heart valves. In one embodiment, the prosthetic heart valve includes a stent and a valve assembly. The stent has a collapsed condition and an expanded condition and includes a plurality of commissure points disposed thereon. The valve assembly is secured to the stent and includes a plurality of leaflets. Each leaflet includes a free edge. An end portion of the free edge of the leaflet is folded and sutured to a corresponding one of the plurality of the commissure points.
In an embodiment of the present invention, the end portions of the free edges of first and second adjacent leaflets are sutured to one another. In another embodiment, the prosthetic heart valve further includes a reinforcement layer disposed between the folded end portions of the free edge of the leaflet.
In certain embodiments of the present invention, the folded end portion of the free edge of the leaflet is generally parallel to the immediately adjacent portions of the leaflet and/or generally perpendicular to the commissure point. In other embodiments, the folded end portion of the free edge of the leaflet is generally perpendicular to the immediately adjacent portions of the leaflet and/or generally parallel to the commissure point.
The free end of the folded end portion of the free edge of the leaflet may extend beyond the suture toward the immediately adjacent portion of the leaflet. In yet another embodiment, the end portion of the free edge of the leaflet may be rolled into a generally spiral configuration. In still another embodiment, the folded end portion of the free edge of the leaflet may include two or more folds.
The end portion of the free edge of the leaflet may wrap at least partially around the commissure point. A web overlying the end portion of the free edge of the leaflet may substantially wrap around the commissure point and may be sutured to be end portion and the commissure point.
Moreover, the leaflet may include “tabs” or ends which are attached to the commissure points or a portion of the attached edge may be sutured thereto.
According to yet another embodiment of the present invention, a prosthetic heart valve includes a stent and a valve assembly disposed within the stent. Each of the stent and the valve assembly has a collapsed condition and an expanded condition. The stent has a proximal end and a distal end. A plurality of commissure points is disposed on the stent. The valve assembly includes a plurality of leaflets, each of which has a free edge. An end portion of the free edge of the leaflet is folded and sutured to a corresponding one of the commissure points. The end portion is folded in a configuration selected from the group consisting of a U-shaped pleat, an S-shaped pleat, a generally spiral roll and a U-shaped pleat enveloped by an external web.
Various embodiments of the present inventions are disclosed herein with reference to the drawings, wherein:
As used herein, the term “proximal,” when used in connection with a prosthetic heart valve, refers to the end of the heart valve closest to the heart when the heart valve is implanted in a patient, whereas the term “distal,” when used in connection with a prosthetic heart valve, refers to the end of the heart valve farthest from the heart when the heart valve is implanted in a patient.
As seen in
The prosthetic heart valve 100 is designed to replace the function of a native aortic valve of a patient. As discussed in detail below, the prosthetic heart valve has an expanded condition and a collapsed condition. Although the invention is described herein as applied to a prosthetic heart valve for replacing a native aortic valve, the invention is not so limited, and may be applied to prosthetic valves for replacing other types of cardiac valves.
The prosthetic heart valve 100 includes a stent or frame 102, which may be wholly or partly formed of any biocompatible material, such as metals, synthetic polymers, or biopolymers capable of functioning as a stent. Suitable biopolymers include, but are not limited to, elastin, and mixtures or composites thereof. Suitable metals include, but are not limited to, cobalt, titanium, nickel, chromium, stainless steel, and alloys thereof, including nitinol. Suitable synthetic polymers for use as a stent include, but are not limited to, thermoplastics, such as polyolefins, polyesters, polyamides, polysulfones, acrylics, polyacrylonitriles, polyetheretherketone (PEEK), and polyaramides. The stent 102 may have an annulus section 110 and an aortic section (not shown). Each of the annulus section 110 and the aortic section of the stent 102 includes a plurality of cells 112 connected to one another around the stent. The annulus section 110 and the aortic section of the stent 102 may include one or more annular rows of cells 112 connected to one another. For instance, the annulus section 110 may have two annular rows of cells 112. When the prosthetic heart valve 100 is in the expanded condition, each cell 112 may be substantially diamond shaped. Regardless of its shape, each cell 112 is formed by a plurality of struts 114. For example, a cell 112 may be formed by four struts 114.
The stent 102 may include commissure points 116 connecting at least two cells 112 in the longitudinal direction of the stent 102. The commissure points 116 may include eyelets for facilitating the suturing of a valve assembly 104 to the stent 102.
The prosthetic heart valve 100 also includes a valve assembly 104 attached inside the annulus section 110 of the stent 102. United States Patent Application Publication Nos. 2008/0228264, filed Mar. 12, 2007; 2008/0147179, filed Dec. 19, 2007; 2005/0113910, filed Jul. 10, 2004; and 2009/0030511, filed Jan. 29, 2009, the entire disclosures of all of which are hereby incorporated herein by reference, describe suitable valve assemblies. The valve assembly 104 may be wholly or partly formed of any suitable biological material or polymer materials in the forms of sheets, non-woven and woven fabrics and the like. Examples of biological materials suitable for the valve assembly 104 include, but are not limited to, porcine or bovine pericardial tissue. Examples of polymers suitable for the valve assembly 104 include, but are not limited to, polyurethane and polyester.
The valve assembly 104 may include a cuff 106 disposed on the lumenal surface of annulus section 110, on the ablumenal surface of annulus section 110, or on both surfaces, and the cuff may cover all or part of either or both of the lumenal and ablumenal surfaces of the annulus section.
Irrespective of the attachment means employed, the leaflets 108 may be attached to the stent 102 along at least some struts 114 of the stent 102 to enhance the structural integrity of the valve assembly 104. As a consequence of this attachment, the struts 114 help support the leaflets 108 of the valve assembly 104 and may therefore reduce the strain in the leaflets.
As shown in
As discussed above, the leaflets 108 may be attached directly to and supported by the struts 114a, 114b, 114c, 114d, 114e, and 114f, such as by suturing. In such event, the cuff 106 may perform little or no supportive function for the leaflets 108, and the thickness of the cuff 106 may, therefore, be reduced. Reducing the thickness of the cuff 106 results in a decrease in the volume of the valve assembly 104 in the collapsed condition. This decreased volume is desirable as it enables the prosthetic heart valve 100 to be implanted in a patient using a delivery device that is smaller than conventional delivery devices. In addition, since the material forming the stent 114 is stronger than the material forming the cuff 106, the stent may perform the supportive function for the leaflets 108 better than the cuff.
The volume of the valve assembly 104 may be further reduced by having the cuff 106 cover only a portion of the surface of annulus section 110. With continued reference to
More particularly, the distal end 120 of the cuff 106 may follow the stent struts 114 up to the commissure points 116, such that the cuff 106 covers all of the cells 112 in the bottom annular row 113 of cells 112 and in a second annular row 115 of cells located between the commissure points and the proximal end 119 of the stent 102, but covers a lesser area of cells in the annular regions between the commissure points. In other words, the distal end 120 of the cuff 106 may be disposed substantially along struts 114a, 114b, 114e, 114f, 114g and 114h, as shown in
As a result of the foregoing configuration, all of the cells 112 in the bottom annular row 113 of cells 112 may be entirely covered by the cuff 106. The cuff 106 may also entirely cover those cells 112 in the second annular row 115 that are located directly below the commissure points 116. All of the other cells 112 in the stent 102 may be open or not covered by the cuff 106. Hence, there may be no cells 112 which are only partially covered by the cuff 106.
Since the edges of the valve leaflets 108 extend up to the second annular row 115 of cells 112 only in the regions of the commissure points 116, there is little to no likelihood of leakage in the area of the cells between the commissure points in the second annular row of cells, and therefore no need for the cuff 106 to cover this area. This reduction in the area of the cuff 106, both at the proximal end 118 and at the distal end 120 thereof, reduces the amount of material in the valve assembly 104, thereby enabling the prosthetic valve 100 to achieve a smaller cross-section in the collapsed condition.
With reference to
The valve assembly 304 may be attached inside the stent 302, and may include a cuff 306 and a plurality of leaflets 308 which collectively function as a one-way valve. The cuff 306 may be located on the inside surface of the stent 302, on the outside surface of the stent, or on both the inside surface and the outside surface. Each leaflet 308 includes an edge 322 attached to the stent 302 and a second free edge 324. An upper portion 328 of the edge 322 may be attached to the stent 302 so as to be disposed substantially along the path of certain struts 314 that lead to the commissure points 316. For example, an upper portion 328 of the edge 322 of at least one leaflet 308 may be attached to, and disposed substantially along, struts 314a and 314b, and an upper portion 328 of the edge 322 of an adjacent leaflet 308 may be attached to, and disposed substantially along, struts 314c and 314d. As such, struts 314a, 314b, 314c, and 314d help support these adjacent leaflets 308. The upper portions 328 of the edges 322 of adjacent leaflets 308 may be attached to the commissure point 316 and struts 314a, 314b, 314c, and 314d using sutures 350. Struts 314b and 314c may each have one end attached to a commissure point 316 and each may be part of the same cell 312.
Alternatively, struts 314b and 314c may be attached directly to one another. Struts 314a and 314b may be connected in an end-to-end fashion, and may be part of different cells 312 that are adjacent to one another. Similarly, struts 314c and 314d may be connected in an end-to-end fashion, and may be part of different cells 312 that are adjacent to one another.
With reference to
The stent 402 may further include one or more commissure points 416 that interconnect two adjacent cells 412 located in one annular row and two other cells 412 located in the next adjacent rows above and below the one row. The commissure points 416 may facilitate the suturing of a valve assembly 404 to the stent 402.
The valve assembly 404 may include a cuff 406 attached to the interior and/or exterior of the stent 402. In addition to the cuff 406, the valve assembly 404 includes a plurality of leaflets 408 attached to the stent 402 and collectively defining a one-way valve. Each leaflet 408 includes a first edge 422 attached to the stent 402 and a second free edge 424. At least one leaflet 408 may be attached to the stent 402 so that the upper portions 428 of its edge 422 are substantially disposed along the path of certain struts 414.
As shown in
In operation, any of the embodiments of the prosthetic heart valve described above may be used to replace a native heart valve, such as the aortic valve. The prosthetic heart valve may be delivered to the desired site (e.g., near a native valve annulus) using any suitable delivery device known in the art. During delivery, the prosthetic heart valve is disposed inside the delivery device in the collapsed condition. The delivery device may be introduced into a patient using the transfemoral, transapical or transseptal approach. Once the delivery device has reached the target site, the user may deploy any of the prosthetic heart valves described above. Upon deployment, the prosthetic heart valve expands into secure engagement within the native valve annulus. When the prosthetic heart valve is properly positioned inside the heart, it works as a one-way valve, allowing blood to flow in one direction and preventing blood from flowing in the opposite direction.
In each of the prosthetic heart valve embodiments described above, the valve assembly preferably is spaced from the distal or aortic end of the stent by a distance that enables deployment of the heart valve by an amount sufficient for the valve leaflets of the prosthetic valve to operate as intended, while the distal end of the stent remains captured by the delivery device. More particularly, the annulus end of the prosthetic heart valve may be deployed first while the aortic end of the prosthetic heart valve remains at least partially covered by the distal sheath of the delivery device. The annulus portion of the prosthetic heart valve may be deployed so that the entirety of the valve leaflets, up to and including the commissures, is deployed and fully operational. By deploying the prosthetic heart valve in this manner, the user can determine whether the valve leaflets are properly positioned relative to the native valve annulus, and whether the valve is functioning properly.
If the user determines that the positioning and operation of the valve are acceptable, the remainder of the valve may be deployed. However, if it is determined that the leaflet position is improper or that the valve is not functioning properly, the user may resheath the valve and either reposition it for redeployment, or remove it entirely from the patient. This can be particularly important in very high risk patients who would typically be recipients of these types of valves, because of the nature of their condition and the impact that may have on the shape and/or condition of the native valve and valve annulus. Of course, the prosthetic heart valve of the present invention can be delivered by deploying the aortic or distal end first as well.
Anatomical irregularities at the implantation site can create issues with respect to the proper functioning and wear of the prosthetic heart valve. Another aspect of the invention is the achievement of a better functioning valve in the various shapes, such as elliptical, round, irregular, etc., that the valve may assume upon implantation and use. This may depend, in some instances, not only on leaflet positioning, commissure positioning, and valve geometry, as previously described, but also can relate to the manner in which the leaflets are attached to the valve assembly, the stent, and in particular, the commissure attachment points. As the stent is deformed by implantation and use, if leaflet positioning and geometry are not correct, undesirable load forces at the leaflet edges, particularly at the commissure attachment points, can be created. This can lead to tearing of the leaflets and/or cuff and eventually valve failure.
Some arrangements that are intended to minimize valve failure and promote better valve function are illustrated in
Referring to
Referring to
Now referring to
The cuff 106 could also be attached to the lumenal surface but disposed between and under the commissure points and the proximal end of the stent. These types of cuff arrangements may also be used in connection with, for example, the embodiments illustrated in
In yet another embodiment illustrated in
Referring now to
As noted, the leaflet 108 may be attached to the commissure point 116 of the stent 102 using any of the configurations previously described. The following will describe the attachment of the leaflet 108 to the commissure point 116 using the configuration of
As noted, the leaflet 108 may be attached to the commissure point 116 of the stent 102 using any of the configurations previously described. Yet another configuration for attaching the leaflet 108 to the commissure point 116 is shown in
Although the invention herein has been described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of the present invention. It is therefore to be understood that numerous modifications may be made to the illustrative embodiments and that other arrangements may be devised without departing from the spirit and scope of the present invention as defined by the appended claims.
It will be appreciated that the various dependent claims and the features set forth therein can be combined in different ways than presented in the initial claims. It will also be appreciated that the features described in connection with individual embodiments may be shared with others of the described embodiments.
The present application is a continuation of U.S. patent application Ser. No. 16/683,516 filed Nov. 14, 2019, which is a continuation of U.S. patent application Ser. No. 15/635,476 filed Jun. 28, 2017, issued as U.S. Pat. No. 10,512,538, which is a continuation of U.S. patent application Ser. No. 13/216,124 filed on Aug. 23, 2011, issued as U.S. Pat. No. 9,717,593, which claims the benefit of the filing date of U.S. Provisional Patent Application No. 61/438,451, filed Feb. 1, 2011, all of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
3657744 | Ersek | Apr 1972 | A |
4275469 | Gabbay | Jun 1981 | A |
4423730 | Gabbay | Jan 1984 | A |
4491986 | Gabbay | Jan 1985 | A |
4580568 | Gianturco | Apr 1986 | A |
4759758 | Gabbay | Jul 1988 | A |
4878906 | Lindemann et al. | Nov 1989 | A |
4922905 | Strecker | May 1990 | A |
4994077 | Dobben | Feb 1991 | A |
5078720 | Burton et al. | Jan 1992 | A |
5391172 | Williams et al. | Feb 1995 | A |
5411552 | Andersen et al. | May 1995 | A |
5415664 | Pinchuk | May 1995 | A |
5456667 | Ham et al. | Oct 1995 | A |
5480423 | Ravenscroft et al. | Jan 1996 | A |
5480424 | Cox | Jan 1996 | A |
5484444 | Braunschweiler et al. | Jan 1996 | A |
5702418 | Ravenscroft | Dec 1997 | A |
5824041 | Lenker et al. | Oct 1998 | A |
5843167 | Dwyer et al. | Dec 1998 | A |
5855601 | Bessler et al. | Jan 1999 | A |
5924424 | Stevens | Jul 1999 | A |
5935163 | Gabbay | Aug 1999 | A |
5961549 | Nguyen et al. | Oct 1999 | A |
5968068 | Dehdashtian | Oct 1999 | A |
5980533 | Holman | Nov 1999 | A |
6077297 | Robinson et al. | Jun 2000 | A |
6083257 | Taylor et al. | Jul 2000 | A |
6090140 | Gabbay | Jul 2000 | A |
6214036 | Letendre et al. | Apr 2001 | B1 |
6264691 | Gabbay | Jul 2001 | B1 |
6267783 | Letendre et al. | Jul 2001 | B1 |
6269819 | Oz et al. | Aug 2001 | B1 |
6306141 | Jervis | Oct 2001 | B1 |
6368348 | Gabbay | Apr 2002 | B1 |
6391050 | Broome | May 2002 | B1 |
6419695 | Gabbay | Jul 2002 | B1 |
6458153 | Bailey et al. | Oct 2002 | B1 |
6468299 | Stack et al. | Oct 2002 | B2 |
6468660 | Ogle et al. | Oct 2002 | B2 |
6488702 | Besselink | Dec 2002 | B1 |
6514261 | Randall | Feb 2003 | B1 |
6517576 | Gabbay | Feb 2003 | B2 |
6533810 | Hankh et al. | Mar 2003 | B2 |
6582464 | Gabbay | Jun 2003 | B2 |
6610088 | Gabbay | Aug 2003 | B1 |
6623518 | Thompson et al. | Sep 2003 | B2 |
6682559 | Myers et al. | Jan 2004 | B2 |
6685625 | Gabbay | Feb 2004 | B2 |
6719789 | Cox | Apr 2004 | B2 |
6730118 | Spenser et al. | May 2004 | B2 |
6736845 | Marquez et al. | May 2004 | B2 |
6783556 | Gabbay | Aug 2004 | B1 |
6790230 | Beyersdorf et al. | Sep 2004 | B2 |
6814746 | Thompson et al. | Nov 2004 | B2 |
6830584 | Seguin | Dec 2004 | B1 |
6869444 | Gabbay | Mar 2005 | B2 |
6893460 | Spenser et al. | May 2005 | B2 |
6908481 | Cribier | Jun 2005 | B2 |
7018406 | Seguin et al. | Mar 2006 | B2 |
7025780 | Gabbay | Apr 2006 | B2 |
7137184 | Schreck | Nov 2006 | B2 |
7160322 | Gabbay | Jan 2007 | B2 |
7247167 | Gabbay | Jul 2007 | B2 |
7267686 | DiMatteo et al. | Sep 2007 | B2 |
7311730 | Gabbay | Dec 2007 | B2 |
7326236 | Andreas et al. | Feb 2008 | B2 |
7329278 | Seguin et al. | Feb 2008 | B2 |
7374573 | Gabbay | May 2008 | B2 |
7381218 | Schreck | Jun 2008 | B2 |
7399315 | Iobbi | Jul 2008 | B2 |
7419501 | Chiu et al. | Sep 2008 | B2 |
7452371 | Pavcnik et al. | Nov 2008 | B2 |
7476244 | Buzzard et al. | Jan 2009 | B2 |
7510572 | Gabbay | Mar 2009 | B2 |
7524331 | Birdsall | Apr 2009 | B2 |
RE40816 | Taylor et al. | Jun 2009 | E |
7585321 | Cribier | Sep 2009 | B2 |
7682390 | Seguin | Mar 2010 | B2 |
7731742 | Schlick et al. | Jun 2010 | B2 |
7803185 | Gabbay | Sep 2010 | B2 |
7846203 | Cribier | Dec 2010 | B2 |
7846204 | Letac et al. | Dec 2010 | B2 |
7914569 | Nguyen et al. | Mar 2011 | B2 |
7967829 | Gunderson | Jun 2011 | B2 |
7993384 | Wu et al. | Aug 2011 | B2 |
8043353 | Kaufmann et al. | Oct 2011 | B2 |
D648854 | Braido | Nov 2011 | S |
D652926 | Braido | Jan 2012 | S |
D652927 | Braido et al. | Jan 2012 | S |
D653341 | Braido et al. | Jan 2012 | S |
D653342 | Braido et al. | Jan 2012 | S |
D653343 | Ness et al. | Jan 2012 | S |
D654169 | Braido | Feb 2012 | S |
D654170 | Braido et al. | Feb 2012 | S |
D660432 | Braido | May 2012 | S |
D660433 | Braido et al. | May 2012 | S |
D660967 | Braido et al. | May 2012 | S |
8313525 | Tuval et al. | Nov 2012 | B2 |
8353955 | Styrc et al. | Jan 2013 | B2 |
8562663 | Mearns et al. | Oct 2013 | B2 |
8568475 | Nguyen et al. | Oct 2013 | B2 |
8652202 | Alon et al. | Feb 2014 | B2 |
8679174 | Ottma et al. | Mar 2014 | B2 |
8778019 | Knippel et al. | Jul 2014 | B2 |
8790386 | Dwork | Jul 2014 | B2 |
8814931 | Wang | Aug 2014 | B2 |
9039759 | Alkhatib et al. | May 2015 | B2 |
20020036220 | Gabbay | Mar 2002 | A1 |
20020045936 | Moe | Apr 2002 | A1 |
20020183827 | Derus et al. | Dec 2002 | A1 |
20030023303 | Palmaz et al. | Jan 2003 | A1 |
20030040792 | Gabbay | Feb 2003 | A1 |
20030050694 | Yang et al. | Mar 2003 | A1 |
20030130726 | Thorpe et al. | Jul 2003 | A1 |
20030144725 | Lombardi | Jul 2003 | A1 |
20040039436 | Spenser et al. | Feb 2004 | A1 |
20040049262 | Obermiller et al. | Mar 2004 | A1 |
20040093060 | Seguin et al. | May 2004 | A1 |
20040093075 | Kuehne | May 2004 | A1 |
20040148009 | Buzzard et al. | Jul 2004 | A1 |
20040186563 | Lobbi | Sep 2004 | A1 |
20040210304 | Seguin et al. | Oct 2004 | A1 |
20040260390 | Sarac et al. | Dec 2004 | A1 |
20050004583 | Oz et al. | Jan 2005 | A1 |
20050027305 | Shiu | Feb 2005 | A1 |
20050033398 | Seguin | Feb 2005 | A1 |
20050049667 | Arbefeuille et al. | Mar 2005 | A1 |
20050080476 | Gunderson et al. | Apr 2005 | A1 |
20050096726 | Sequin et al. | May 2005 | A1 |
20050137687 | Salahieh et al. | Jun 2005 | A1 |
20050137688 | Salahieh et al. | Jun 2005 | A1 |
20050137691 | Salahieh et al. | Jun 2005 | A1 |
20050137695 | Salahieh et al. | Jun 2005 | A1 |
20050137697 | Salahieh et al. | Jun 2005 | A1 |
20050149159 | Andreas | Jul 2005 | A1 |
20050240200 | Bergheim | Oct 2005 | A1 |
20050240254 | Austin | Oct 2005 | A1 |
20050256566 | Gabbay | Nov 2005 | A1 |
20060008497 | Gabbay | Jan 2006 | A1 |
20060025857 | Bergheim et al. | Feb 2006 | A1 |
20060058872 | Salahieh et al. | Mar 2006 | A1 |
20060074484 | Huber | Apr 2006 | A1 |
20060106415 | Gabbay | May 2006 | A1 |
20060122692 | Gilad et al. | Jun 2006 | A1 |
20060142848 | Gabbay | Jun 2006 | A1 |
20060149360 | Schwammenthal et al. | Jul 2006 | A1 |
20060167468 | Gabbay | Jul 2006 | A1 |
20060173532 | Flagle et al. | Aug 2006 | A1 |
20060178740 | Stacchino et al. | Aug 2006 | A1 |
20060195180 | Kheradvar et al. | Aug 2006 | A1 |
20060206202 | Bonhoeffer et al. | Sep 2006 | A1 |
20060241744 | Beith | Oct 2006 | A1 |
20060241745 | Solem | Oct 2006 | A1 |
20060259120 | Vongphakdy et al. | Nov 2006 | A1 |
20060259136 | Nguyen et al. | Nov 2006 | A1 |
20060259137 | Artof et al. | Nov 2006 | A1 |
20060265056 | Nguyen et al. | Nov 2006 | A1 |
20060276813 | Greenberg | Dec 2006 | A1 |
20060282150 | Olson et al. | Dec 2006 | A1 |
20060282157 | Hill et al. | Dec 2006 | A1 |
20070010876 | Salahieh et al. | Jan 2007 | A1 |
20070027534 | Bergheim et al. | Feb 2007 | A1 |
20070043435 | Seguin et al. | Feb 2007 | A1 |
20070055358 | Krolik et al. | Mar 2007 | A1 |
20070067029 | Gabbay | Mar 2007 | A1 |
20070073391 | Bourang | Mar 2007 | A1 |
20070088431 | Bourang | Apr 2007 | A1 |
20070093890 | Eliasen et al. | Apr 2007 | A1 |
20070100435 | Case et al. | May 2007 | A1 |
20070112422 | Dehdashtian | May 2007 | A1 |
20070118210 | Pinchuk | May 2007 | A1 |
20070156225 | George et al. | Jul 2007 | A1 |
20070162100 | Gabbay | Jul 2007 | A1 |
20070168013 | Douglas | Jul 2007 | A1 |
20070203575 | Forster | Aug 2007 | A1 |
20070213813 | Von Segesser et al. | Sep 2007 | A1 |
20070233228 | Eberhardt et al. | Oct 2007 | A1 |
20070239271 | Nguyen | Oct 2007 | A1 |
20070244545 | Birdsall et al. | Oct 2007 | A1 |
20070244552 | Salahieh et al. | Oct 2007 | A1 |
20070260301 | Chuter et al. | Nov 2007 | A1 |
20070288087 | Fearnot et al. | Dec 2007 | A1 |
20080004688 | Spenser et al. | Jan 2008 | A1 |
20080004696 | Vesely | Jan 2008 | A1 |
20080009940 | Cribier | Jan 2008 | A1 |
20080021552 | Gabbay | Jan 2008 | A1 |
20080039934 | Styrc | Feb 2008 | A1 |
20080071369 | Tuval et al. | Mar 2008 | A1 |
20080082159 | Tseng | Apr 2008 | A1 |
20080082164 | Friedman | Apr 2008 | A1 |
20080097595 | Gabbay | Apr 2008 | A1 |
20080114452 | Gabbay | May 2008 | A1 |
20080125853 | Bailey et al. | May 2008 | A1 |
20080140189 | Nguyen et al. | Jun 2008 | A1 |
20080147179 | Cai et al. | Jun 2008 | A1 |
20080147182 | Righini | Jun 2008 | A1 |
20080147183 | Styrc | Jun 2008 | A1 |
20080154355 | Benichou et al. | Jun 2008 | A1 |
20080154356 | Obermiller et al. | Jun 2008 | A1 |
20080228264 | Li et al. | Sep 2008 | A1 |
20080243245 | Thambar et al. | Oct 2008 | A1 |
20080255662 | Stacchino et al. | Oct 2008 | A1 |
20080262602 | Wilk et al. | Oct 2008 | A1 |
20080269878 | Tobbi | Oct 2008 | A1 |
20080269879 | Sathe et al. | Oct 2008 | A1 |
20090024137 | Chuter | Jan 2009 | A1 |
20090054975 | Del Nido | Feb 2009 | A1 |
20090105798 | Koch | Apr 2009 | A1 |
20090112309 | Jaramillo et al. | Apr 2009 | A1 |
20090118826 | Khaghani | May 2009 | A1 |
20090138079 | Tuval et al. | May 2009 | A1 |
20090157175 | Benichou | Jun 2009 | A1 |
20090192585 | Bloom | Jul 2009 | A1 |
20090216310 | Straubinger | Aug 2009 | A1 |
20090216312 | Straubinger et al. | Aug 2009 | A1 |
20090240320 | Tuval et al. | Sep 2009 | A1 |
20090287299 | Tabor et al. | Nov 2009 | A1 |
20100004740 | Seguin et al. | Jan 2010 | A1 |
20100023120 | Holecek | Jan 2010 | A1 |
20100036484 | Hariton et al. | Feb 2010 | A1 |
20100049306 | House et al. | Feb 2010 | A1 |
20100049313 | Alon et al. | Feb 2010 | A1 |
20100082094 | Quadri et al. | Apr 2010 | A1 |
20100087907 | Lattouf | Apr 2010 | A1 |
20100114305 | Kang et al. | May 2010 | A1 |
20100121434 | Paul et al. | May 2010 | A1 |
20100131055 | Case et al. | May 2010 | A1 |
20100168778 | Braido | Jul 2010 | A1 |
20100168839 | Braido et al. | Jul 2010 | A1 |
20100174290 | Wuebbeling | Jul 2010 | A1 |
20100185277 | Braido et al. | Jul 2010 | A1 |
20100191326 | Alkhatib | Jul 2010 | A1 |
20100204781 | Alkhatib | Aug 2010 | A1 |
20100204785 | Alkhatib | Aug 2010 | A1 |
20100217382 | Chau et al. | Aug 2010 | A1 |
20100249911 | Alkhatib | Sep 2010 | A1 |
20100249923 | Alkhatib et al. | Sep 2010 | A1 |
20100262231 | Tuval et al. | Oct 2010 | A1 |
20100286768 | Alkhatib | Nov 2010 | A1 |
20100298931 | Quadri et al. | Nov 2010 | A1 |
20110029072 | Gabbay | Feb 2011 | A1 |
20110208298 | Tuval et al. | Aug 2011 | A1 |
20110224678 | Gabbay | Sep 2011 | A1 |
20110282425 | Dwork | Nov 2011 | A1 |
20110288626 | Straubinger et al. | Nov 2011 | A1 |
20110295216 | Miller | Dec 2011 | A1 |
20120022635 | Yamashita | Jan 2012 | A1 |
20120053574 | Murray, III et al. | Mar 2012 | A1 |
20120071969 | Li et al. | Mar 2012 | A1 |
20120078352 | Wang et al. | Mar 2012 | A1 |
20120089223 | Nguyen | Apr 2012 | A1 |
20120197391 | Alkhatib et al. | Aug 2012 | A1 |
20120310332 | Murray et al. | Dec 2012 | A1 |
20130030520 | Lee et al. | Jan 2013 | A1 |
20130079869 | Straubinger et al. | Mar 2013 | A1 |
20130138118 | Doyle | May 2013 | A1 |
20130231735 | Deem | Sep 2013 | A1 |
20130304179 | Bialas | Nov 2013 | A1 |
20140067050 | Costello et al. | Mar 2014 | A1 |
20140135909 | Carr et al. | May 2014 | A1 |
20140343670 | Bakis | Nov 2014 | A1 |
20150305867 | Liu | Oct 2015 | A1 |
20170056169 | Johnson | Mar 2017 | A1 |
Number | Date | Country |
---|---|---|
2011202175 | Jul 2011 | AU |
101953725 | Jan 2011 | CN |
19857887 | Jul 2000 | DE |
20000659 | May 2001 | DE |
10121210 | Nov 2002 | DE |
102005003632 | Aug 2006 | DE |
202008008610 | Sep 2008 | DE |
202008009610 | Dec 2008 | DE |
0051451 | May 1982 | EP |
0850607 | Jul 1998 | EP |
0856300 | Aug 1998 | EP |
1000590 | May 2000 | EP |
1129744 | Sep 2001 | EP |
1157673 | Nov 2001 | EP |
1360942 | Nov 2003 | EP |
1584306 | Oct 2005 | EP |
1598031 | Nov 2005 | EP |
1872743 | Jan 2008 | EP |
1926455 | Jun 2008 | EP |
1229865 | Nov 2010 | EP |
2850008 | Jul 2004 | FR |
2847800 | Oct 2005 | FR |
2001504717 | Apr 2001 | JP |
2003334254 | Nov 2003 | JP |
2004130074 | Apr 2004 | JP |
2010504820 | Feb 2010 | JP |
2010523234 | Jul 2010 | JP |
2010526609 | Aug 2010 | JP |
2010528761 | Aug 2010 | JP |
2010531193 | Sep 2010 | JP |
2010540079 | Dec 2010 | JP |
2011512922 | Apr 2011 | JP |
2012500665 | Jan 2012 | JP |
5351959 | Nov 2013 | JP |
9117720 | Nov 1991 | WO |
9716133 | May 1997 | WO |
9829057 | Jul 1998 | WO |
9832412 | Jul 1998 | WO |
9913801 | Mar 1999 | WO |
9930646 | Jun 1999 | WO |
0018330 | Apr 2000 | WO |
0044313 | Aug 2000 | WO |
0069368 | Nov 2000 | WO |
0119285 | Mar 2001 | WO |
200128459 | Apr 2001 | WO |
200149213 | Jul 2001 | WO |
0154625 | Aug 2001 | WO |
0156500 | Aug 2001 | WO |
0158384 | Aug 2001 | WO |
0176510 | Oct 2001 | WO |
0236048 | May 2002 | WO |
0247575 | Jun 2002 | WO |
02067782 | Sep 2002 | WO |
2003047468 | Jun 2003 | WO |
2005070343 | Aug 2005 | WO |
06073626 | Jul 2006 | WO |
2006127756 | Nov 2006 | WO |
2006127765 | Nov 2006 | WO |
2007071436 | Jun 2007 | WO |
2008042266 | Apr 2008 | WO |
08070797 | Jun 2008 | WO |
2008125153 | Oct 2008 | WO |
2008138584 | Nov 2008 | WO |
2008150529 | Dec 2008 | WO |
2009001309 | Dec 2008 | WO |
2009011866 | Jan 2009 | WO |
2009029199 | Mar 2009 | WO |
2009042196 | Apr 2009 | WO |
2009045338 | Apr 2009 | WO |
2009061389 | May 2009 | WO |
2009091509 | Jul 2009 | WO |
2009108615 | Sep 2009 | WO |
2009149462 | Dec 2009 | WO |
2010008548 | Jan 2010 | WO |
2010008549 | Jan 2010 | WO |
2010051025 | May 2010 | WO |
2010087975 | Aug 2010 | WO |
2010096176 | Aug 2010 | WO |
2010098857 | Sep 2010 | WO |
2010141626 | Dec 2010 | WO |
2011147849 | Dec 2011 | WO |
2011137531 | Jan 2012 | WO |
2012026965 | Mar 2012 | WO |
2012036741 | Mar 2012 | WO |
2012048035 | Apr 2012 | WO |
2016059084 | Apr 2016 | WO |
Entry |
---|
International Search Report Application No. PCT/US2011/048963, dated Dec. 15, 2011. |
International Search Report Application No. PCT/US2011/048989, dated Dec. 15, 2011. |
International Search Report Application No. PCT/US2011/048967, dated Dec. 15, 2011. |
International Search Report and Written Opinion for Application No. PCT/US2011/001615 dated Jul. 11, 2012. |
Alkhatib, U.S. Appl. No. 13/216,124, filed Aug. 23, 2011, titled “Leaflet Suturing to Commissure Points for Prosthetic Heart Valve”. |
International Search Report for Application No. PCT/US2011/001597 dated Mar. 7, 2012. |
Knippel, U.S. Appl. No. 13/234,782, filed Sep. 16, 2011, titled “Staged Deployment Devices and Method for Transcatheter Heart Valve Delivery”. |
Morris, U.S. Appl. No. 13/788,820, filed Mar. 7, 2013, titled “Devices and Methods for Transcatheter Heart Valve Delivery”. |
Wang, U.S. Appl. No. 13/212,442, filed Aug. 18, 2011, titled “Staged Deployment Devices and Methods for Transcatheter Heart Valve Delivery Systems”. |
International Search Report for Application No. PCT/US2011/001450 dated Mar. 5, 2012. |
Australian Examination Report for Application No. 2011293898 dated Jul. 26, 2013. |
International Search Report and Written Opinion for Application No. PCT/US2013/039407 dated Feb. 10, 2014. |
International Search Report and Written Opinion for Application No. PCT/US2011/001450 dated Mar. 5, 2012. |
Walther et al., “Transapical approach for sutureless stent-fixed aortic valve implantation: experimental results”; European Journal of Cardio-thoracic Surgery 29 (2006) 703-708 (Jan. 30, 2006). |
Todd M. Dewey et al., “Transapical aortic valve implantation: an animal feasibility study”; The annals of thoracic surgery 2006; 82: 110-116 (Feb. 13, 2006). |
Samuel V. Lichtenstein et al., “Transapical Transcatheter Aortic Valve Implantation in Humans”, Circulation. 2006; 114: 591-596 (Jul. 31, 2006). |
Christoph H. Huber, et al., “Direct-Access Valve Replacement”, Journal of the American College of Cardiology, vol. 46 No. 2, pp. 366-370, (Jul. 19, 2005). |
M. J. Mack, “Minimally invasive cardiac surgery”, Surgical Endoscopy, 2006, 20:S488-S492, DOI: 10.1007/s00464-006-0110-8 (presented Apr. 24, 2006). |
John G. Webb et al., “Percutaneous Aortic Valve Implantation Retrograde From the Femoral Artery”, Circulation, 2006; 113:842-850 (Feb. 6, 2006). |
Samuel V. Lichtenstein, “Closed heart surgery: Back to the future”, The Journal of Thoracic and Cardiovascular Surgery, vol. 131, No. 5, pp. 941-943, May 2006. |
Textbook “Transcatheter Valve Repair”, 2006, pp. 165-186. |
Ruiz, Carlos, Overview of PRE-CE Mark Transcatheter Aortic Valve Technologies, Euro PCR, dated May 25, 2010. |
Quaden, Rene, et al., Percutaneous aortic valve replacement: resection before implantation, 836-840,European J. of Cardio-thoracic Surgery, 27 (2005). |
Knudsen, L.L., et al., Catheter-implanted prosthetic heart valves, The International Journal of Artificial Organs, vol. 16, No. 5 1993, pp. 253-262. |
Moazami, Nader, et al., Transluminal Aortic Valve Placement, Moazami, ASAIO Journal, 1996; 42:M381-M385. |
Andersen, Henning Rud, Transluminal Catheter Implanted Prosthetic Heart Valves, International Journal of Angiology 7:102-106 (1998). |
Andersen, H. R., et al., Transluminal implantation of artificial heart valves, European Heart Journal (1992) 13, 704-708. |
Zegdi, Rachid, Md, Phd et al., Is It Reasonable to Treat All Calcified Stenotic Aortic Valves With a Valved Stent?, 679-584, J. of the American College of Cardiology, vol. 51, No. 5, Feb. 5, 2008. |
Braido, et al., U.S. Appl. No. 29/375,243, filed Sep. 20, 2010, titled “Surgical Stent Assembly”. |
Braido, U.S. Appl. No. 29/375,260, filed Sep. 20, 2010, titled “Forked Ends”. |
European Search Report for Application No. EP15171169.4 dated Oct. 16, 2015. |
Supplementary European Search Report for Application EP11857681.8 dated Nov. 16, 2017. |
Pavenik et al., “Aortic and venous valve for percutaneous insertion,” Minimally Invasive Therapy & Allied Technologies, 9:3-4 (2000), 287-292. |
Martin, Caitlin, Thuy Pham, and Wei Sun, “Significant differences in the material properties between aged human and porcine aortic tissues,” European Journal of Cardio-Thoracic Surgery, 40.1 (2011), 28-34. |
Sauren, A.A.H.J et al., “The mechanical properties of porcine aortic valve tissues,” Journal of Biomechanics, 16.5 (1983), 327-337. |
Gundiah, Namrata et al., “Asymmetric mechanical properties of porcine aortic sinuses,” The Annals of Thoracic Surgery, 85.5 (2008), 1631-1638. |
Gundiah, Namrata et la., “Significant material property differences between the porcine ascending aorta and aortic sinuses,” Journal of Heart Valve Disease, 17.6 (2008), 606-613. |
Extended European Search Report and Written Opinion for EP11820608.5 dated Mar. 5, 2018. |
European Search Report for Application No. EP 21165142, dated Jul. 8, 2021, 7 pages. |
Extended European Search Report for U.S. Appl. No. 16/196,712 dated May 9, 2017. |
Grube et al., “Percutaneous Aortic Valve Replacement for Severe Aortic Stenosis in High-Risk Patients Using the Second- and Current Third-Generation Self-Expanding CoreValve Prosthesis”, JACC, (Jul. 3, 2007), vol. 50, No. 1, doi:10.1016/j.jacc.2007.04.047, pp. 69-76, XP029653338. |
International Search Report and Written Opinion for Application No. PCT/US2014/064253 dated Feb. 3, 2015. |
International Search Report and Written Opinion for PCT/US2018/031973, dated Oct. 19, 2018. |
International Search Report from PCT/US2017/063893, dated Feb. 7, 2018, 3 pages. |
Japanese Office Action for Application No. 2013-525891 dated May 8, 2015. |
Overview of PRE-CE Mark Transcatheter Aortic Valve Technologies (powerpoint—dated Jun. 1, 2010). |
Walther et al., “Transapical approach for sutureless stent-fixed aortic valve implantation: experimental results”, European Journal of Cardio thoracic Surgery, vol. 29(5), pp. 703-708 (Jan. 3, 2006). |
Notice of Opposition Filed Against EP2670351 (Jun. 27, 2023) 56 pages. |
Number | Date | Country | |
---|---|---|---|
20220296366 A1 | Sep 2022 | US |
Number | Date | Country | |
---|---|---|---|
61438451 | Feb 2011 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16683516 | Nov 2019 | US |
Child | 17698546 | US | |
Parent | 15635476 | Jun 2017 | US |
Child | 16683516 | US | |
Parent | 13216124 | Aug 2011 | US |
Child | 15635476 | US |